Ventilation Associated Pneumonia and Covid-19

Centre Hospitalier Universitaire de Nīmes268 enrolled

Overview

In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.

Study Type

OBSERVATIONAL

Enrollment

268

Conditions

SARS-CoV2 Infection Ventilator Associated Pneumonia Ards COVID-19

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years * Positive SARS-Cov-2 polymerase chain reaction (PCR) * healthcare associated pneumonia Exclusion Criteria : Patient opposition to participate to the study

Outcomes

Primary Outcomes

VAP ecological difference between the first and second waves of COVID

Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2

Time frame: January 2020 to January 2021

Secondary Outcomes

proportion of fungal co-infections

Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave

Time frame: January 2020 to January 2021

duration of mechanical ventilation

Number of days under mechanical ventilations

Time frame: Day 28

number of days of organ failure

number of days between first organ failure and no organ failure (discharge from intensive care)

Time frame: Day 28

Mortality

proportion of patients deceased at day 28

Time frame: Day 28

proportion of patients treated with corticosteroid therapy

Time frame: Day 28

probabilistic antibiotic therapy at admission

probabilistic antibiotic therapy prescribed at admission

Time frame: Day 1

antiviral treatment

proportion of patients treated with antiviral treatment

Time frame: Day 28

Ventilation Associated Pneumonia and Covid-19

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes